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Background: Bone mineral density (BMD), as an indicator of cumulative estrogen exposure, may be reduced in
female patients with psychotic disorder (van der Leeuw et al., 2013), possibly reﬂecting reduced cerebral
exposure to estrogen and alterations in neuroprotective effects. To the degree that BMD is a marker of cu-
mulative (endogenous) estrogen exposure, we hypothesized that BMDwould be positively associated with
cerebral gray and white matter indices.
Methods: Dual X-ray absorptiometry (DEXA) andmagnetic resonance (MRI) scans were acquired in fourteen fe-
male patients diagnosed with a psychotic disorder. BMD was expressed in total BMD (g/cm2), Z- and T-scores.
Cerebral cortical thickness (CT) (as indicator of gray matter status) and fractional anisotropy (FA) (as indicator
of white matter integrity) were measured and served as the dependent variables in multilevel random regres-
sion models. BMD measures were the independent variables.
Results: Femoral BMDmeasures were positively associated with CT at trend signiﬁcance (total BMD: B = 0.266,
95% CI:−0.019–0.552, p = 0.067; Z-score: B = 0.034, 95% CI: 0.001–0.067, p = 0.046; T-score: B = 0.034, 95%
CI: 0.000–0.068, p = 0.052). There were no signiﬁcant associations between femoral BMD measures and FA.
Conclusions: The data suggest that in womenwith psychotic disorder, alterations in the neuroprotective effect of
estrogen (asmeasured by BMD) impact cortical graymatter, but not whitematter integrity. These ﬁndingsmerit
further investigation and, if replicated, would lend support to the estrogen hypothesis of schizophrenia.© 2013 Elsevier B.V. All rights reserved.1. Introduction
Gender differences in the incidence and course of schizophrenia
have been ascribed to neuroprotective effects of endogenous estrogen
in females. In early adulthood, incidence rates of schizophrenia are
lower in women than in men, and the age at onset of schizophrenia
occurs three to four years later in women (Riecher-Rossler and
Hafner, 1993, 2000; Hafner et al., 1998; Halbreich and Kahn, 2003;
Markham, 2011). However, when estrogen levels decline around
menopause, women display a second peak in the incidence of schizo-
phrenia, which is absent in men (Riecher-Rossler and Hafner, 1993;
Hafner et al., 1998; Abel et al., 2010). In the premenopausal period,
female patients generally tend to fare better than their male counter-
parts, displaying a less severe course of symptoms, with a superior
response to antipsychotic (AP) treatment and better social outcome
(Seeman, 1983, 1996; Hafner et al., 1998; Salem and Kring, 1998;chology, Maastricht University
erlands. Tel.: +31 43 3883928;
. Marcelis).
ghts reserved.Hafner, 2003; Abel et al., 2010; Markham, 2011). Also, symptom var-
iability during the menstrual cycle has been reported. Amelioration
of symptoms is associated with a rise in estrogen and more clinical
admissions take place during low estrogen phases (Riecher-Rossler
et al., 1994; Seeman, 1996; Huber et al., 2004).
There are two (related) estrogen hypotheses of schizophrenia: 1) the
hypoestrogenism or deﬁciency hypothesis which describes (chronic)
gonadal dysfunction in women with schizophrenia, and 2) the pro-
tection hypothesis which states that estrogen exerts a relative pro-
tection against schizophrenia in premenopausal women (Riecher-
Rossler and Hafner, 1993; Riecher-Rossler, 2002). The neuroprotective
mechanismof estrogen in the humanbrain is complex. It includes struc-
tural effects such as the conservation of neurons, stimulation of growth
and synaptogenesis, aswell as effects at the receptor level, i.e. preserva-
tion of neurotransmitter receptors and modulation of neurotransmis-
sion (Brann et al., 2007; Boerma et al., 2010; Liu et al., 2010; Azcoitia
et al., 2011; Kulkarni et al., 2012; McEwen et al., 2012).
The dysconnectivity hypothesis of schizophrenia proposes that
altered structural connectivity may represent a key pathological mech-
anism in schizophrenia (Friston, 1998; Konrad and Winterer, 2008).
The estrogen and dysconnectivity theories are possibly linked. Recently,
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potential association between sex steroid hormones, white matter
(WM) indices and functional connectivity in the human brain, and
concluded that gonadal hormones appear to organize and activate
structural connections within the brain. Animal studies have shown
that sex steroid hormones play an essential role in myelination (Peper
et al., 2011b). In humans, sex steroids have been associated with struc-
tural brain development during puberty, exerting effects on both white
(Asato et al., 2010; Herting et al., 2011; Peper et al., 2011a) and gray
matter (Neufang et al., 2009; Peper et al., 2009, 2011a).
Other evidence for associations between estrogen and gray matter
comes from the work of Goldstein et al. (2001, 2002) showing disrup-
tion of the normal sexual dimorphism in schizophrenia, particularly in
the cortex. In addition, hormonal ﬂuctuations during the menstrual
cycle (Protopopescu et al., 2008; Pletzer et al., 2010) and hormonal
contraceptive use (Pletzer et al., 2010) have been associated with gray
matter changes inwomen of childbearing age. In the context of estrogen
therapy (ET) and its effect on the aging brain in postmenopausal women,
both higher and lower gray matter concentrations in speciﬁc cortical
areas have been suggested (Boccardi et al., 2006; Robertson et al., 2009;
Lord et al., 2010). Animalmodels ofmultiple sclerosis have demonstrated
prophylactic effects of estrogen with regard to gray matter atrophy
(Mackenzie-Graham et al., 2012). Thus, disparate research ﬁelds have
provided clues as to the relationship between estrogen and cerebral
structure at different life stages. However, studies investigating cumula-
tive estrogen exposure and brain structure in patients with psychotic
disorder have, to the best of our knowledge, not been conducted.
Previously, we used dual X-ray absorptiometry (DEXA) to assess
bone mineral density (BMD) as a marker of cumulative estrogen expo-
sure (Clemons and Goss, 2001), and found that reduced femoral BMD
was associated with being female and having a psychotic disorder, but
not with familial risk for psychotic disorder. This suggests that unique
environmental factors, contributing to primary low estrogen levels in
women, may impact the risk of developing a psychotic disorder, in sup-
port of the estrogen (deﬁciency) hypothesis of schizophrenia (van der
Leeuw et al., 2013).
The aim of the current studywas to investigate the potential asso-
ciation between endogenous estrogen exposure (as indexed by BMD,
corrected for exogenous estrogen exposure such as contraceptives) and
gray and white matter indices in this female patient group. Using mag-
netic resonance imaging (MRI) and diffusion tensor imaging (DTI), corti-
cal thickness (CT) and white matter integrity (represented by fractional
anisotropy (FA)) were assessed respectively. We hypothesized that
both CT and FA would be positively associated with BMD, reﬂecting
the neuroprotective effects of estrogen in schizophrenia.
2. Methods and materials
2.1. Subjects
Data was collected in the context of an ongoing multicenter lon-
gitudinal study (Genetic Risk and Outcome of Psychosis, G.R.O.U.P.)
in the Netherlands. In selected representative geographic areas in
the Netherlands and Belgium, patients presenting consecutively at men-
tal health services either as outpatients or inpatients were recruited for
the study. Patients between the ages of 16 and 50 years, with a diagnosis
of non-organic, non-affective psychosis according to DSM-IV criteria,
were included (Korver et al., 2012). Sufﬁcient command of the Dutch
languagewasmandatory. A complete description of the recruiting proto-
col of the MRI sub-study is provided by Habets et al. (2011).
As mentioned in the introduction, the aim of the current study was
to investigate associations between BMD and brain measures in female
patients with a psychotic disorder, as a reduction in BMD (possibly
reﬂecting low endogenous estrogen levels) was previously found in fe-
male (n = 16), but not inmale (n = 46) patients (van der Leeuwet al.,
2013). A T1-weighted structural MRI scan was obtained in 14, and anadditional DTI scan in 13 of the original 16 female patients. Thus, the
present study sample comprised 14 female patients.
The sample included eight patients who were diagnosed with
schizophrenia, one patient with schizoaffective disorder, four pa-
tients with a diagnosis of psychotic disorder not otherwise speciﬁed
and one patient with a diagnosis of brief psychotic disorder. Patients
were genetically unrelated. The mean illness duration was 6.6 years.
Prior to DEXA acquisition, participants were screened for the follow-
ing exclusion criteria: 1) metabolic or endocrinologic disease, 2) dietary
deﬁciency or eating disorder, 3) medication: corticosteroids, thyroxin,
anti-epileptics, heparin, lithium, cytostatic agents, 4) (semi-) profes-
sional athletes, 5) polydipsia (N3 l/day), 6) pregnancy, and 7) hormonal
(infertility) treatment. Exclusion criteria for MRI constituted: 1) head
injury with loss of consciousness for a duration of more than 1 h, 2)
meningitis of other neurological diseases that might affect brain struc-
ture or function, 3) cardiac arrhythmia requiring medical treatment,
4) severe claustrophobia, 5) (suspected) pregnancy, and 6) any metal
foreign object in the body, including the presence of an intrauterine
device.
2.2. Measures
2.2.1. Age at menarche and dysmenorrhea
Age at menarche and the occurrence of menstrual irregularity were
assessed. Dysmenorrhea was speciﬁed as altered duration and/or fre-
quency ofmenses or the absence of two ormoremenses during the pre-
vious three months. Amenorrhea was deﬁned as the absence of menses
for at least three months.
2.2.2. Use of contraceptive drugs (exogenous estrogen exposure)
Cumulative (lifetime) exogenous estrogen exposure in women was
expressed in micrograms, as the product of daily dose and total days
of use.
2.2.3. Substance use
Substance use was assessed using the composite international di-
agnostic interview (CIDI). Cannabis use was assessed as the reported
lifetime frequency of use. Other drug use, such as stimulants, sedatives,
opiates, cocaine, PCP, psychedelics, inhalants or other (e.g. ecstasy,
poppers) was assessed in the same way. Alcohol use was deﬁned as the
average number ofweekly consumptions during the previous 12 months.
Tobacco use was deﬁned as the number of cigarettes per day, in the past
year.
2.2.4. Antipsychotic medication (AP) exposure
Current AP usewas classiﬁed by type: “prolactin-raising” APs, in this
study comprising ﬁrst-generation APs, risperidone and amisulpride; or
“prolactin-sparing” APs, comprising second or third-generation APs
with the exception of risperidone and amisulpride. Subjects who were
AP-free at the time of the investigations were placed in the prolactin-
sparing group.
Previous AP use was assessed retrospectively by self-report. Best
estimate lifetime (cumulative) AP exposure was determined by multi-
plying the number of days of AP use with the daily AP dose converted
to haloperidol equivalents (in milligrams), and summing all periods of
use. Lifetime exposure was calculated for all APs and separately for
prolactin-raising APs.
2.3. DEXA acquisition and processing
DEXA scans were acquired at Maastricht University Medical Centre
with aHologic Discovery A (TrompMedical, Castricum, theNetherlands)
(NHANES and Ethnic Reference Data). DEXA scans were performed
in two anatomical areas: the lumbar spine, vertebrae L2 through
L4; and the proximal left femur, speciﬁcally the collum, trochanter
major, intertrochanteric area and Ward's triangle. BMD measures
116 C. van der Leeuw et al. / Schizophrenia Research 150 (2013) 114–120were expressed as total BMD in grams per square centimeter (g/cm2),
Z-scores and T-scores. The Z-score compares an individual's BMD with
the mean BMD of a comparable population (with respect to gender,
age and ethnicity). The T-score compares an individual's BMD to
peak bone mass (PBM). Peak bone mass is the highest BMD an indi-
vidual is expected to acquire during life. The T-score is used to diagnose
osteopenia and osteoporosis. In the present study, the three femoral
BMDmeasures were a priori used for further analysis, as these were re-
duced in female patients (van der Leeuw et al., 2013).
2.4. MRI acquisition and processing
Magnetic resonance imaging scans were obtained at Maastricht
University, the Netherlands, using an Allegra syngo MR A30 (Siemens,
Erlangen, Germany) operating at 3.0 T. The following anatomical scan
parameters were used: Modiﬁed Driven Equilibrium Fourier Transform
(MDEFT) sequence; 176 slices, 1 mm isotropic voxel size, echo time
2.4 ms, repetition time 7.92 ms, inversion time 910 ms, ﬂip angle
15°, total acquisition time 12 min 51 s; Magnetization Prepared Rapid
Acquisition Gradient-Echo (MPRAGE; Alzheimer's Disease Neuroimaging
Initiative) sequence 192 slices, 1 mm isotropic voxel size, echo time
2.6 ms, repetition time 2250 ms, inversion time 900 ms, ﬂip angle 9°,
and total acquisition time 7 min 23 s. The matrix size was 256 × 256
and ﬁeld of view was 256 × 256 mm2. The number of excitations was
one. Two similar sequenceswere used because of a scanner update dur-
ing data collection.
Microstructural anatomy was examined using diffusion tensor im-
aging with an echo-planar-imaging sequence (ﬁeld of view 230 mm2,
TR 10800 ms, TE 84 ms, voxel size 1.8 × 1.8 × 1.8 mm3, b-value
1000 s/mm2, noise level 40, 85 slices, no overlap). As a result of the
scanner update, two DTI sequences were used: one with 76 directions
(of which 4 T2-weighted (B0) and 72 diffusion-weighted (B)), and
one with 81 directions (8 × B0 and 73 × B). Total acquisition time of
the DTI sequence was 15 min.
2.4.1. Cortical thickness measurement
Scans were processed and analyzed using Freesurfer stable release
v5.0.0, http://surfer.nmr.mgh.harvard.edu (Dale et al., 1999; Fischl et al.,
1999; Fischl and Dale, 2000; Fischl et al., 2002; Segonne et al., 2004).
To measure CT, the cerebral cortex was parcellated into units based
on gyral and sulcal structure (Fischl et al., 2004; Desikan et al., 2006).
Furthermore, a variety of surface-based data was created including
maps of curvature and sulcal depth. This method uses both intensity
and continuity information from the entire three dimensional MR vol-
ume in segmentation and deformation procedures to produce represen-
tations of CT, calculated as the closest distance from the gray/white
matter boundary to the gray matter/CSF boundary at each vertex on
the tessellated surface (Fischl and Dale, 2000). The maps are created
using spatial intensity gradients across tissue classes and are not re-
stricted to the voxel resolution of the original data, thus are capable of
detecting sub-millimeter differences between groups. CT measurement
procedures have been validated against histological analysis (Rosas
et al., 2002) and manual measurements (Kuperberg et al., 2003; Salat
et al., 2004). Individual CT values for each predeﬁned region of interest
(hereafter: ROI; adapted from the Desikan atlas (Desikan et al., 2006),
34 ROIs per hemisphere) were derived by FreeSurfer and exported to
STATA version 12 (StataCorp). Thus, every individual had 68 CT mea-
surements over the predeﬁned ROIs in both hemispheres.
2.4.2. Diffusion tensor imaging analysis
Processing of DTI data was effectuated using tract-based spatial
statistics (TBSS) v1.2 in FSL 4.1.6 (FMRIB Analysis Group, Oxford,
UK, http://www.fmrib.ox.ac.uk/analysis/research/tbss). First, standard
Siemens DICOM ﬁles were transformed into compressed NIFTI format
using a custom built in-house software named GIANT (General Image
ANalysis Tools developed by EHBMG). Raw data were corrected forhead movement and eddy currents invoked during scanning. The B0
volume was skull-stripped using FSL's Brain Extraction Tool (Smith,
2002) and this served as a brain mask for all B volumes.
The next stepwasﬁtting a diffusion tensormodel at each voxel using
data output from the brain extraction, diffusion weighted data and
gradient directions following a general linear model (FreeSurfer). After
tensor ﬁtting the process continued working on FA volumes, eroding
them slightly.
Nonlinear registration aligned each FA volume to 1 × 1 × 1 mm
standard FMRIB58_FA space. The standard FMRIB58_FA contains a tem-
plate derived from high-resolution images of 58 participants in a well-
aligned population (both males and females ranging between 20 and
50 years of age) (Smith et al., 2006).
After nonlinear transformation of the FA volumes into standard
space, a mean FA skeleton from all participants per group was derived.
The mean FA skeleton follows the major white matter tracts in each in-
dividual participant (normalized in MNI152 space) and provides a way
to compare between (groups of) participants. The ﬁnal step of the pro-
cessing was setting the FA threshold using visual inspection of the FA
skeleton, in the present study at a level of 0.25, to include major white
matter tracts whilst removing small peripheral tracts that would cause
excess interparticipant variability. In addition, this threshold setting
avoided inclusion of regions that are likely to be composed of multiple
tissue types or ﬁber orientations.
The Johns Hopkins University International Consortium for Brain
Mapping (JHU ICBM)-DTI-81 white-matter atlas labels (Mori et al.,
2008) were used to assign speciﬁc tract names. From all 38 JHU labeled
white matter tracts, mean FA values were extracted and exported to
STATA.
This study was approved by the standing ethics committee. All sub-
jects provided written informed consent in accordance with the
committee's guidelines.
2.5. Statistical analyses
Conform previous work in this sample (Habets et al., 2011),
datasets were transformed from a wide to a long format resulting in a
hierarchical structure, with 68 regional CT measures and 38 FA values
(level 1) nested in respectively 14 and 13 subjects (level 2). Given the
clustering of brain measures compromising statistical independence
of the observations, multilevel random regression models were ﬁtted
(Goldstein, 1987) using the XTREG command in STATA (StataCorp, ver-
sion 12). Separate analyses were conducted for CT and FA. CT and FA
were the dependent variables, and BMD measures were the indepen-
dent variables. Although BMDmeasureswere acquired in both the lum-
bar spine and the proximal femur, the current analyses were conducted
a priori with the femoral BMD measures (total BMD, Z-score, T-score),
as the previously reported reduction in BMDwas speciﬁc for the proxi-
mal femur (van der Leeuw et al., 2013).
Analyses were adjusted for the a priori hypothesized confounders:
age at scan, age at menarche, dysmenorrhea, cumulative exogenous
estrogen exposure, lifetime exposure to cannabis and current use of
prolactin-raising AP (0 = no AP or prolactin-sparing AP, 1 = prolactin-
raising AP). In separate analyses, cumulative prolactin-raising AP expo-
surewas entered in themodel replacing current prolactin-raising AP use.
Since lifetime AP exposure is a much debated potential confounder
in neuroimaging research, sensitivity analyses were carried out using
lifetime exposure to all AP as a covariate, instead of present and cumu-
lative prolactin-raising AP use.
3. Results
3.1. Descriptive analyses
The mean age at the time of investigation was 27 years. There were
six participants with dysmenorrhea. The rate of substance use in the
Table 2
Mean femoral BMD, CT and FA.
Mean ± SD
Total femoral BMD (g/cm2) 0.923 ± 0.109
Z-score −0.193 ± 0.984
T-score −0.257 ± 0.971
CT (n = 14) 2.553 ± 0.375
FA (n = 13) 0.576 ± 0.086
SD: standard deviation.
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AP medication at the time of the investigation. Three women used
olanzapine, twowomenused aripiprazole, onewomanused quetiapine,
three women used risperidone, one woman used amisulpride, and one
woman used haloperidol. Hence, ﬁve patients used a prolactin-raising
AP at the time of the study. None of the patients were AP-naïve and the
majority (with the exception of one individual) had used a prolactin-
raising AP at some point during their lives.
The use of additional psychotropic medication was minimal, and
consisted of three participants with antidepressant use (of which two
selective serotonin reuptake inhibitors (SSRI) and one with a serotonin
and noradrenalin reuptake inhibitor (SNRI)).
Themean femoral BMDmeasures, aswell as themean CT and FA are
shown in Table 2.
3.2. Associations between BMD and CT
BMD measures of the femur were positively associated with CT
when correcting for current exposure to a prolactin-raising AP
(total BMD: B = 0.266, 95% CI: −0.019–0.552, p = 0.067; Z-score:
B = 0.034, 95% CI: 0.001–0.067, p = 0.046; T-score: B = 0.034,
95% CI: 0.000–0.068, p = 0.052) (Table 3).When correcting for lifetime
exposure to prolactin-raising AP, the positive association was strength-
ened (total BMD: B = 0.429, 95% CI: 0.104–0.753, p = 0.010; Z-score:
B = 0.049, 95% CI: 0.012–0.085, p = 0.009; T-score: B = 0.048,
95% CI: 0.011–0.086, p = 0.011) (Table 3). As described under the
heading Statistical analysis, a sensitivity analysis was carried out
with lifetime exposure to all AP replacing present or cumulative exposure
to prolactin-raising AP as a covariate. The positive association between
femoral BMD measures and CT remained (total BMD: B = 0.390, 95%
CI: 0.091–0.689, p = 0.011; Z-score: B = 0.046, 95% CI: 0.012–0.080,
p = 0.008; T-score: B = 0.046, 95% CI: 0.011–0.081, p = 0.010).
3.3. Associations between BMD and FA
There were no signiﬁcant associations between femoral BMD mea-
sures and FA (Table 3). Substitution of either covariate pertaining to
prolactin-raising AP use with lifetime exposure to all AP did not alter
the pattern of ﬁndings.
4. Discussion
The present study examined, for the ﬁrst time — to the best of our
knowledge, associations between cumulative endogenous estrogen ex-
posure (to the extent that it is reﬂected by femoral BMD) and brain
structure in psychotic disorder. Our ﬁndings tentatively suggest that
higher cumulative exposure to estrogen is associated with increased
cerebral cortical thickness. There was no evidence for a signiﬁcant asso-
ciation between cumulative estrogen exposure and microstructural
white matter integrity.Table 1
Demographic characteristics (n = 14).
Demographic characteristic Mean ± SD
Age at scan (years) 27.64 ± 8.48
Age at menarche 13.0 ± 0.96
Dysmenorrhea (n) 6
Lifetime exogenous estrogen exposure (μg) 29923 ± 43477
Smoking (cigarettes per day) 6.21 ± 8.01
Alcohol use (units per week) 0.92 ± 1.21
Cannabis use (number of times lifetime) 17.71 ± 34.60
Other drug use (number of times lifetime) 18.71 ± 44.97
Present exposure to PRL-raising AP (yes/no) 5/9
Cumulative (lifetime) exposure to PRL-raising AP (hal. eq.) 2262 ± 2506
Cumulative (lifetime) exposure to all AP (hal. eq.) 3006 ± 3197
SD: standard deviation; PRL-raising: prolactin-raising; AP: antipsychotic medication; hal.
eq.: haloperidol equivalents (in milligrams).4.1. Findings
4.1.1. Cumulative endogenous estrogen exposure and CT
Our ﬁndings showed positive associations between BMD measures
and CT in female patients with a psychotic disorder. In other words,
higher cumulative estrogen levels may be associated with increased
CT, or lower estrogen levels may be associatedwith reduced CT. Assum-
ing that the association is true, a deﬁciency in estrogen exposure may
impact graymatter, whichmay be reversed by higher levels of estrogen
that may induce or activate neuroprotective mechanisms. The results
thus ﬁt both the estrogen deﬁciency and protection hypothesis.
Accumulating clinical research has demonstrated emerging treat-
ment perspectives of estrogen therapy (ET) and selective estrogen re-
ceptor modulators (SERMs) as adjunctive therapy (Kulkarni et al.,
2010, 2012). Following an earlier, inconclusive Cochrane review (Chua
et al., 2005), a quantitative 2012 review suggests that the use of estro-
gen as adjunctive treatment for schizophrenia could be effective in
women (Begemann et al., 2012). Though this indicates an association
betweenhypoestrogenismandpsychotic disorders inwomen, the ques-
tion remainswhether hypoestrogenism is a cause or consequence of the
disease (Aston et al., 2010; Markham, 2011), or its treatment.
Interpretation of the current study ﬁndings is complicated by the
cross-sectional nature of the data, as well as the fact that no previous
studies have been conducted combining (markers of) estrogen levels
and structural brain alterations in psychiatrically ill individuals. Never-
theless, disrupted sexual dimorphisms in the cortex of patients with
schizophrenia as demonstrated by MRI (Goldstein et al., 2002) were
reported over a decade ago, which helped refuel the debate about sex
differences in schizophrenia. It seems biologically plausible that estro-
gen, through its impact on brain morphology, contributes to the risk
of – and the sex differences in – psychotic disorder. Indirect support
for this comes from a study in healthy postmenopausal women, show-
ing beneﬁcial inﬂuence of ET on the cortical cerebral surface (Boccardi
et al., 2006). However, other groups failed to discover an association
between ET and total gray matter (Low et al., 2006; Ha et al., 2007),
or reported a negative association (Greenberg et al., 2006). During
adolescence, higher estrogen levels are related to an overall decrease
in cortical graymatter (Peper et al., 2009, 2011a), demonstrating that the
organizing and structural effects of estrogen may be age-dependent and
inﬂuenced by other factors.
4.1.2. Cumulative endogenous estrogen exposure and FA
We did not ﬁnd an association between BMD and FA. The literature
on associations between estrogen and cerebral white matter is limited.
In the developing brain, white matter increase is minimal in girls com-
pared to boys, and white matter maturation may be primarily under
the inﬂuence of luteinizing hormone (which is positively associated
with white matter in puberty) (Peper et al., 2011a). In one study, estro-
gen was positively related to FA in boys, yet negatively related to FA in
girls (Herting et al., 2011). One reason for the absence of an association
between estrogen and FA in the current study, may be that other go-
nadal hormones constitute the principal hormonal effect on white
matter, e.g. progesterone elicits the production of myelin and oligo-
dendrocytes (Peper et al., 2011b). Results from studies investigating
the effect of ET on white matter in the aging brain are inconsistent.
Low et al. (2006) reported inconclusive ﬁndings with regard to the
Table 3
Associations between femoral BMD and structural brain measures.
Total BMD Z-score T-score
B (95% CI), p-value B (95% CI), p-value B (95% CI), p-value
CT (n = 14)
Correction for:
Present exposure PRL-raising AP 0.266 (−0.019–0.552), 0.067 0.034 (0.001–0.067), 0.046 0.034 (0.000–0.068), 0.052
Cumulative exposure PRL-raising AP 0.429 (0.104–0.753), 0.010 0.049 (0.012–0.085), 0.009 0.048 (0.011–0.086), 0.011
FA (n = 13)
Correction for:
Present exposure PRL-raising AP 0.002 (−0.134–0.138), 0.973 0.000 (−0.015–0.015), 0.993 0.000 (−0.015–0.015), 0.992
Cumulative exposure PRL-raising AP 0.012 (−0.287–0.311), 0.937 −0.001 (−0.027–0.026), 0.970 −0.001 (−0.028–0.026), 0.941
B's represent unstandardized regression coefﬁcients of the multilevel regression analyses. CI: conﬁdence interval; PRL-raising AP: prolactin-raising antipsychotic medication.
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niﬁcantly greater white matter volumes in estrogen users.
4.2. Inﬂuence of AP on brain measures and BMD
AP exposure may be associated with both brain measures and BMD
andmay thus act as a potential confounder. With regard to the effect on
brain structure, some studies found, in fairly large samples, no effect of
duration of AP use or illness duration on white matter microstructure
(Kanaan et al., 2009) or gray matter (Leung et al., 2011). In contrast, a
large prospective study (vanHaren et al., 2011) found that cortical thin-
ning is a progressive process and is in part mediated by the use of AP. A
recentmeta-review (Shepherd et al., 2012) reported that structural brain
changes (including cortical volume) may be affected by AP, though the
effect of AP exposure may itself be confounded by disease progression
(Ho et al., 2011).
In the current study, we initially corrected for the present use of a
prolactin-raising AP or cumulative exposure to prolactin-raising AP, in
linewith our hypothesis that cerebral estrogen exposuremay be affected
by hyperprolactinemia-induced hypogonadism secondary to prolactin-
raising AP. When using lifetime exposure to all AP instead of current or
lifetime prolactin-raising AP use in the analyses, the positive associations
between BMDand CT remained, and the absence of associations between
BMD and FA was conﬁrmed.
With regard to the relation between AP and BMD, the majority of
studies are suggestive of a negative association (Crews and Howes,
2012). In our original BMD study (n = 16), we found a negative main
effect of prolactin-raising AP on lumbar BMD, but not femoral BMD
(van der Leeuw et al., 2013). In addition, due to a reduction in sample
size (and concomitant effect size reduction) when excluding female
patients who used prolactin-raising APs, we were unable to exclude
the possibility of AP exposure as a partial explanation for reduced BMD
in female patients. However, the speciﬁc association between BMD and
CT (and not FA) in the present study, corrected for present and lifetime
prolactin-raising AP use and cumulative exposure to all AP, is at least
suggestive of an independent cerebral effect of primary estrogen reduc-
tion in female patients with psychotic disorder.
4.3. Methodological considerations
Certain limitations in our study design need to be acknowledged.
First, bone mineral density was used as an indirect indicator of
cumulative (endogenous) estrogen exposure and has disadvantages be-
cause it is inﬂuenced bymany hormonal and non-hormonal factors and
should thus be interpreted as a proxy marker. Nevertheless, the most
important potential confounding factorswere addressed. A clear advan-
tage of BMD is that it reﬂects cumulative exposure to estrogen, while
the direct measurement of estrogen in serum or urine is a momentary
assessment. Although we could not consider the inﬂuence of the
phase of the menstrual cycle on brain morphology as recommended
by Pletzer et al. (2010), we adjusted for several hormonal factorssuch as age at menarche, dysmenorrhea, lifetime contraceptive use
and current and lifetime prolactin-raising AP use.
Second, the sample size of the study was small, suggesting that our
ﬁndings are best interpreted as hypothesis-generating. The sample
size did not preclude the detection of positive ﬁndings in CT. However,
it is possible that our study lacked power to detect an effect in FA. To
date, other neuroimaging studies investigating estrogen effects on brain
morphology in schizophrenia have not been performed and the present
hypothesis-generating study therefore requires replication with
larger sample sizes, to corroborate or challenge the results. The presented
cross-sectional data is part of a longitudinal study. Follow-up data may
provide further clues to the relationship between lifetime estrogen expo-
sure and brain alteration (over time) in psychotic disorder.
Third, it is possible that the effects of estrogen are region-speciﬁc.
The present study was not powered to examine whether the impact of
BMD varied with speciﬁc CT or FA regions (i.e. BMD × region interac-
tion). To discern regions of interest, an experimental treatment study
using ET or SERMs may offer additional insights.
Fourth, our study is limited by the fact that our subjects were not
ﬁrst-episode AP-naïve patients. Inherent to the inclusion criteria of the
GROUP study, individuals with a relatively recent onset of psychotic
disorder were included (mean illness duration of 6.6 years). Thus, by
implication, none of our patients were AP-naïve and the majority had
used a prolactin-raising AP at some point in their lives. Nevertheless,
the pattern of results remained consistent after extensive correction for
AP use. Ideally, replication should be performed in a sample that has
been exposed to neither AP nor contraconceptive drugs.
4.4. Conclusions
Reduced BMD (reﬂecting low cumulative estrogen levels) in female
patients with a psychotic disorder may be associated with decreased
cortical thickness, suggesting that a diminished neuroprotective effect
of estrogenmay contribute to cerebral graymatter alterations, indirectly
supporting both aspects (deﬁciency and protection) of the estrogen
hypothesis of schizophrenia. There was no evidence for an association
between BMD and white matter integrity.
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